Avior Wealth Management LLC Has $4.65 Million Position in Johnson & Johnson $JNJ

Key Points

• Avior Wealth Management LLC increased its stake in Johnson & Johnson by 9.0%, holding 30,409 shares valued at approximately $4.65 million as of the latest filing.
• Johnson & Johnson reported a quarterly earnings per share (EPS) of $2.77, beating estimates and showing a 5.8% revenue growth year-over-year during the last reported quarter.
• The company recently declared a quarterly dividend of $1.30 per share, representing a 2.9% yield and a dividend payout ratio of 55.61%.

Avior Wealth Management LLC boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,409 shares of the company's stock after purchasing an additional 2,510 shares during the quarter. Avior Wealth Management LLC's holdings in Johnson & Johnson were worth $4,645,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Neumann Capital Management LLC boosted its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Neumann Capital Management LLC now owns 14,894 shares of the company's stock worth $2,275,000 after purchasing an additional 100 shares in the last quarter. XY Planning Network Inc. acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $359,000. Uncommon Cents Investing LLC boosted its holdings in Johnson & Johnson by 5.2% in the second quarter. Uncommon Cents Investing LLC now owns 30,369 shares of the company's stock worth $4,639,000 after acquiring an additional 1,488 shares in the last quarter. TBH Global Asset Management LLC grew its stake in Johnson & Johnson by 1.6% in the second quarter. TBH Global Asset Management LLC now owns 17,328 shares of the company's stock valued at $2,647,000 after acquiring an additional 268 shares during the period. Finally, Tiller Private Wealth Inc. bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $295,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $179.69 on Monday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company's 50 day moving average price is $174.41 and its two-hundred day moving average price is $162.05. The stock has a market cap of $432.75 billion, a P/E ratio of 19.22, a P/E/G ratio of 2.29 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the business posted $2.82 earnings per share. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JNJ. Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research report on Friday, September 19th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $181.40.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.